Egeberg A, et al. - This trial incorporated an evaluation of the safety, efficacy, and time to discontinuation (drug survival) of biologics (adalimumab, etanercept, infliximab, secukinumab, and ustekinumab) in the treatment of moderate-to-severe plaque psoriasis. Furthermore, a comparison was performed of the originators with biosimilars (i.e. Enbrel with Benepali, and Remicade with Remsima). It was determined that ustekinumab correlated with the highest drug survival, and secukinumab with the lowest, despite the fact that maximum patients on secukinumab were non-naive. A shift from the originator to biosimilar did not exert any notable impact on drug survival, and the safety profiles were comparable. Secukinumab frequently reported the occurrence of adverse events. In order to gauge the long-term safety of novel biologics for psoriasis, advanced research was warranted.